# Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

> **NCT00598793** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 242 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart
- **DRUG:** insulin glargine
- **DRUG:** metformin
- **DRUG:** pioglitazone

## Key facts

- **NCT ID:** NCT00598793
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00598793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00598793, "Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00598793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*